Pharmabiz20h
VYNE Therapeutics reports positive phase 1a SAD data for VYN202, a novel BD2-selective BET inhibitor
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, announced positive data from the single ascending dose (SAD) portion of its ongoing phase 1a trial of VYN202. The phase 1a trial is ...
Pharmabiz22h
J&J seeks EU approval of nipocalimab to treat people living with generalised myasthenia gravis
Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of the Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking first approval of ...
Pharmabiz23h
Aura Biosciences announces positive results from phase 2 end of study of bel-sar as a first-line treatment for early-stage choroidal melanoma
Aura Biosciences announces positive results from phase 2 end of study of bel-sar as a first-line treatment for early-stage choroidal melanoma: Boston Saturday, September 14, 2024, ...
Pharmabiz1d
Halozyme announces US FDA approval of Roche's Tecentriq Hybreza with Enhanze for multiple types of cancer
Halozyme announces US FDA approval of Roche's Tecentriq Hybreza with Enhanze for multiple types of cancer: San Diego Saturday, September 14, 2024, 12:00 Hrs [IST] Halozyme Therape ...
Pharmabiz1d
ICMR signs MoA with industry and academic partners to advance first-in-human phase 1 clinical trials
ICMR signs MoA with industry and academic partners to advance first-in-human phase 1 clinical trials: Our Bureau, New Delhi Saturday, September 14, 2024, 14:10 Hrs [IST] In a step ...
Pharmabiz1d
Qiagen extends partnership with Bio-Manguinhos to enhance malaria, dengue detection in Brazil’s national screening programmes
Venlo, the Netherlands Saturday, September 14, 2024, 14:00 Hrs [IST] ...
Pharmabiz1d
Nona Biosciences collaborates with Umoja Biopharma to advance in vivo CAR-T cell therapies
Nona Biosciences collaborates with Umoja Biopharma to advance in vivo CAR-T cell therapies: Cambridge, Massachusetts Saturday, September 14, 2024, 11:00 Hrs [IST] Nona Biosciences ...
Pharmabiz1d
FibroBiologics seeks US FDA patent for generation of three-dimensional organoids using fibroblast cell-based technology
FibroBiologics seeks US FDA patent for generation of three-dimensional organoids using fibroblast cell-based technology: Houston Saturday, September 14, 2024, 17:00 Hrs [IST] Fibr ...
Pharmabiz1d
Singular Genomics gets non-binding acquisition proposal from Deerfield Management Company
Singular Genomics gets non-binding acquisition proposal from Deerfield Management Company: San Diego Saturday, September 14, 2024, 15:00 Hrs [IST] Singular Genomics Systems, Inc, ...
Pharmabiz1d
GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma
GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...
Pharmabiz1d
Biology opens up new frontiers in medicine to cure genetic diseases: Kiran Mazumdar Shaw
Biology opens up new frontiers in medicine to cure genetic diseases: Kiran Mazumdar Shaw: Nandita Vijayasimha, Bengaluru ...
Pharmabiz1d
Studies on sickle cell trait and blood clots finding impact all Black/African American populations
Studies on sickle cell trait and blood clots finding impact all Black/African American populations: Sunnyvale, California Saturday, September 14, 2024, 13:00 Hrs [IST] 23andMe Hol ...